Cargando…

Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis

OBJECTIVE: To identify and quantify the adverse effects associated with the recombinant human papillomavirus (types 6, 11, 16 and 18) vaccine in adolescents. DATA SOURCE: Systematic review of randomized clinical trials from PubMed, SciELO and Lilacs databases. Articles investigating the safety of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Pedro Luiz Spinelli, Calestini, Gustavo Lacerda da Silva, Alvo, Fernando Salgueiro, Freitas, Jefferson Michel de Moura, Castro, Paula Marcela Vilela, Konstantyner, Tulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2015
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685569/ https://www.ncbi.nlm.nih.gov/pubmed/26376359 http://dx.doi.org/10.1016/j.rpped.2015.02.006

Ejemplares similares

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women
por: Ji, Jia, et al.
Publicado: (2012)

Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)
por: Liu, Yu-Ying, et al.
Publicado: (2021)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
por: Teixeira, Cirbia Silva Campos, et al.
Publicado: (2017)

Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer
por: de Araújo Catão Zampronha, Rossana, et al.
Publicado: (2013)

Simultaneous Detection and Differentiation of Human Papillomavirus Genotypes 6, 11, 16 and 18 by AllGlo Quadruplex Quantitative PCR
por: Yu, Daojun, et al.
Publicado: (2012)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012)

Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age
por: Zahreddine, Monica, et al.
Publicado: (2020)

Sexual behavior and infection with cervical human papillomavirus types 16 and 18
por: Itarat, Yuwadee, et al.
Publicado: (2019)

Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16.
por: Arends, M. J., et al.
Publicado: (1995)

Detection of Human Papillomavirus Types 6/11, 16 and 18 in Exfoliated Cells from the Uterine Cervices of Japanese Women with and without Lesions
por: Yokota, Harushige, et al.
Publicado: (1990)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
por: de Sanjosé, Silvia, et al.
Publicado: (2019)

Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
por: Huh, Warner K., et al.
Publicado: (2014)

Prevalence of Human Papillomavirus subtypes 16 and 18 among Yemeni Patients with Cervical Cancer
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2017)

Human Papillomavirus 16 and 18 Infection in Oral Cancer in Thailand: A Multicenter Study
por: Komolmalai, Nicha, et al.
Publicado: (2020)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Peng, Shiwen, et al.
Publicado: (2021)

Human Papillomavirus Types 16 and 18 Early-expressed Proteins Differentially Modulate the Cellular Redox State and DNA Damage
por: Cruz-Gregorio, Alfredo, et al.
Publicado: (2018)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

CD8 T-Cell Responses in Incident and Prevalent Human Papillomavirus Types 16 and 18 Infections
por: Coleman, Hannah N., et al.
Publicado: (2012)

Frequency of Human Papillomavirus (HPV) 16 and 18 Detection in Paraffin- Embedded Laryngeal Carcinoma Tissue
por: Hosseini, Seyed Zinab, et al.
Publicado: (2017)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18
por: Zhao, Li, et al.
Publicado: (2011)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Replication interference between human papillomavirus types 16 and 18 mediated by heterologous E1 helicases
por: Mori, Seiichiro, et al.
Publicado: (2014)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

Methylation of the L1 gene and integration of human papillomavirus 16 and 18 in cervical carcinoma and premalignant lesions
por: Torres-Rojas, Francisco Israel, et al.
Publicado: (2018)

Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada
por: Gauthier, Barbara, et al.
Publicado: (2019)

Differential expression of human papillomavirus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasia
por: Baba, Satoshi, et al.
Publicado: (2020)

Ancient Evolutionary History of Human Papillomavirus Type 16, 18 and 58 Variants Prevalent Exclusively in Japan
por: Tanaka, Kohsei, et al.
Publicado: (2022)

Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer
por: Ma, Yanyun, et al.
Publicado: (2022)

Expression of human papillomavirus 16 and 18 DNA in oral lichen planus using polymerase chain reaction
por: Vijayan, Aswathy K., et al.
Publicado: (2022)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen
por: Granadillo, Milaid, et al.
Publicado: (2013)

Maturation of the Human Papillomavirus 16 Capsid
por: Cardone, Giovanni, et al.
Publicado: (2014)

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
por: Halfon, Philippe, et al.
Publicado: (2010)

Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
por: Ramanakumar, Agnihotram V, et al.
Publicado: (2010)

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_unqpb1oa78ga60v23f831g10g9